Samsung Bioepis Taking Steps to List Iteslf on the NASDAQ
Samsung Bioepis Taking Steps to List Iteslf on the NASDAQ
  • Korea IT Times (
  • 승인 2015.07.28 10:48
  • 댓글 0
이 기사를 공유합니다

Samsung Bioepis, a bio-pharmaceutical unit of Samsung Group, is taking steps to list itself on the NASDAQ market by March 2016.

A top-ranking official at Samsung Bioepis said on July 26, “We are set to enter the process of selecting a lead manager for our listing in March 2016. We will send a request for proposal to a group of securities firms in and outside Korea within this week and complete the selection by August 15.”

The official added, “We aim to raise 2 trillion won through listing on the NASDAQ. Samsung Bioepis would be the first bio-drug company that attempts to raise a 2-trillion-won fund through an IPO on the NASDAQ market.”

Considering that Samsung Bioepis is estimated by the market to have a corporate value of about 10 trillion won, the 2-trillion-won IPO is not an excessive goal. Samsung Bioepis expects its corporate value to be recognized most highly in next March when its first biosimilar product would garner the approval for sales in overseas markets.

Samsung Bioepis expects the European Medicines Agency to approve the sales of its biosimilar SB4 sometime between February and March 2016.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: / Editorial Div. 02-578-0434 / 010-2442-9446. Email:
  • Publisher: Monica Younsoo Chung. CEO: Lee Kap-soo. Editor: Jung Yeon-jin. Juvenile Protection Manager: Yeon Choul-woong.
  • IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.